Baidu
map

XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果

2018-12-25 MedSci MedSci原创

安斯泰来制药公司和辉瑞公司近日宣布,在评估XTANDI(恩杂鲁胺)的III期ARCHES试验中,与单独使用雄激素剥夺疗法(ADT)相比,XTANDI联合ADT在转移性激素敏感性前列腺癌(mHSPC)男性患者的治疗中达到了其主要终点,显著改善了患者的无进展生存期(rPFS)。

安斯泰来制药公司和辉瑞公司近日宣布,在评估XTANDI(恩杂鲁胺)的IIIARCHES试验中,与单独使用雄激素剥夺疗法(ADT)相比,XTANDI联合ADT在转移性激素敏感性前列腺癌(mHSPC)男性患者的治疗中达到了其主要终点,显著改善了患者的无进展生存期(rPFS)。ARCHES试验的初步安全性结果与先前在去势抵抗性前列腺癌(CRPC)的临床试验中的安全性结果一致。

辉瑞全球产品肿瘤学首席开发官,医学博士Mace Rothenberg说:虽然XTANDI目前被批准用于转移性和非转移性CRPC,但对于患有转移性激素敏感性前列腺癌的男性仍然需要更多的治疗选择。凭借这些重要的结果,我们相信XTANDI有可能帮助那些患有转移性激素敏感性的前列腺癌患者。安斯泰来肿瘤学发展部高级副总裁兼全球治疗领域主管Steven Benner说:根据ARCHES的最新结果,我们期待与相关卫生部门讨论临床数据,以支持扩大XTANDI的适应症。”XTANDI目前在美国和日本被批准用于治疗CRPC,并且在欧盟用于治疗转移性和高风险的非转移性CRPC。自2012年首次获得批准以来,XTANDI已被累计用于全球330,000名男性。


原始出处:

http://www.firstwordpharma.com/node/1612946#axzz5aJrWexZu

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Mon Jul 01 16:55:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916059, encodeId=469819160592e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Mar 26 03:55:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat Jun 29 11:55:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286385, encodeId=66e3128638576, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386458, encodeId=5cd813864587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388439, encodeId=248d13884395b, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Mon Jul 01 16:55:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916059, encodeId=469819160592e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Mar 26 03:55:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat Jun 29 11:55:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286385, encodeId=66e3128638576, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386458, encodeId=5cd813864587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388439, encodeId=248d13884395b, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2019-03-26 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Mon Jul 01 16:55:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916059, encodeId=469819160592e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Mar 26 03:55:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat Jun 29 11:55:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286385, encodeId=66e3128638576, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386458, encodeId=5cd813864587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388439, encodeId=248d13884395b, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2019-06-29 lingaifan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Mon Jul 01 16:55:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916059, encodeId=469819160592e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Mar 26 03:55:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat Jun 29 11:55:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286385, encodeId=66e3128638576, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386458, encodeId=5cd813864587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388439, encodeId=248d13884395b, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Mon Jul 01 16:55:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916059, encodeId=469819160592e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Mar 26 03:55:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat Jun 29 11:55:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286385, encodeId=66e3128638576, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386458, encodeId=5cd813864587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388439, encodeId=248d13884395b, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Mon Jul 01 16:55:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916059, encodeId=469819160592e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Mar 26 03:55:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat Jun 29 11:55:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286385, encodeId=66e3128638576, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386458, encodeId=5cd813864587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388439, encodeId=248d13884395b, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Mon Jul 01 16:55:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916059, encodeId=469819160592e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Mar 26 03:55:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653713, encodeId=82311653e1359, content=<a href='/topic/show?id=64ab18861b7' target=_blank style='color:#2F92EE;'>#Xtandi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18861, encryptionId=64ab18861b7, topicName=Xtandi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f30024340037, createdName=lingaifan, createdTime=Sat Jun 29 11:55:00 CST 2019, time=2019-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286385, encodeId=66e3128638576, content=<a href='/topic/show?id=24395268347' target=_blank style='color:#2F92EE;'>#性激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52683, encryptionId=24395268347, topicName=性激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386458, encodeId=5cd813864587e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388439, encodeId=248d13884395b, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594549, encodeId=509b159454922, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Dec 27 08:55:00 CST 2018, time=2018-12-27, status=1, ipAttribution=)]

相关资讯

Nat Commun:原发性前列腺癌整体表观遗传学分类研究

雄激素受体(AR)是前列腺癌中的关键驱使转录因子,受表观遗传学的紧密调控。到目前为止,大多数表观遗传学分析都在细胞系或者有限的组织样本中进行。最近,有研究人员为了综合的研究原发性前列腺癌的表观遗传学背景,在100个前列腺癌肿瘤中对AR和组蛋白修饰标记(H3K27ac, H3K4me3, H3K27me3)进行了RNA-seq和ChIP-seq分析。研究发现,5种数据类型的整体分子亚型阐释了3种主要

Nat commun:NSD2是转移性前列腺癌的保守驱使因子

破译体内细胞内在转移过程的相关机制对开发鉴定新的治疗方法是非常必要的。最近,有研究人员通过对遗传工程小鼠模型(GEMM)和人类前列腺癌相关性研究的分析,阐释了转移性前列腺癌恶化过程中的细胞内在驱使因子。研究人员通过对来源自小鼠原发性肿瘤家系标记的细胞的表达分析和转移瘤分析确定了转移起始的一个特性。跨物种主调控因子分析比较了上述小鼠特性和人类相似特性,从而鉴定了转移过程中的一个保守的驱使因子,并且具

盘点:前列腺癌机理盘点

【1】Brit J Cancer:激素原发性多病灶前列腺癌和匹配的淋巴结转移转录组探索 目前对原发性前列腺癌(PC)预测能力的不足将会导致该疾病发生转移,同样导致良性PCs的过度治疗和恶性PCs的治疗不足。最近,有研究人员探索了多病灶激素原发性PC转移过程发生过程中的转录变化情况。研究人员使用了RNA测序的方法分析了23个激光显微切割原发性PC病灶位点和23个临近的正常前列腺组织样本

Prostate Cancer P D:生殖细胞系BRCA2变异频率的增加与前列腺癌转移相关

BRCA2中生殖系细胞变异与更高风险的前列腺癌(PCa)相关,并且最近报道了高频率BRCA1和BRCA2(BRCA1/2)基因变异在转移去势难治性PCa样本中存在。BRCA2变异在不同的种族人口中不同,包括了非裔美国人(AA)和美国白种人(CA)。最近,有研究人员对BRCA1和BRCA2基因进行了测序,样本来源于1240名PCa患者的血液DNA,包括了30%的患者。研究人员将其分成3个不同的群体,

CLIN CANCER RES:BMI1促进前列腺癌转移

远处转移是前列腺癌患者死亡的主要原因。遗传构成和种族等因素在治疗中起着至关重要的作用。CLIN CANCER RES近期发表了一篇文章,研究BMI1在高加索人和非裔美国人中与转移性前列腺癌的相关性。

盘点:前列腺治疗方法进展

【1】Eur J Cancer Care (Engl):接受新药物治疗的前列腺癌患者的疲劳、治疗满意度和健康相关生活质量研究 临床研究已经阐释了醋酸阿比特龙+强的松(AAP)和恩杂鲁胺(ENZ)在显著改善转移性去势难治性前列腺癌患(mCRPC)者生存中的作用。然而,考虑到患者现实生活中的经历,尤其是考虑到疲劳、治疗满意度和健康生活质量(HRQoL),相关的研究很有限。最近,有研究人员

Baidu
map
Baidu
map
Baidu
map